Tumor-associated macrophages (TAMs) are the predominant immune population within the tumor microenvironment (TME), playing a key role in promoting tumor growth and establishing an immunosuppressive environment that facilitate immune evasion. Here we report that the immune receptor CD300e is highly expressed by TAM in colorectal (CRC) and drives their immunosuppressive and pro-tumorigenic, correlating with reduced expression of MHC-II molecules, essential for antigen presentation. In vitro, CD300e-deficient macrophages exhibit enhanced pro-inflammatory activity and phagocytic capacity, coupled with reduced efferocytosis, suggesting a critical role for CD300e in promoting tumor progression. The depletion of CD300e, in vivo, results in a reduced tumor burden and enhanced survival in CRC mouse models, accompanied by a more robust anti-tumor immune response characterized by increased infiltration of activated CD4+ and CD8+ T cells producing IFN-γ. Our study provides comprehensive insights into the roles of CD300e in myeloid cells in CRC, highlighting its potential as a therapeutic target for reprogramming TAMs to support anti-tumor immunity.
CD300e as a Driver of Immunosuppressive Tumor Microenvironment in Colorectal Cancer
Barizza, AnnicaInvestigation
;Vassallo, StefaniaInvestigation
;Masatti, LauraFormal Analysis
;Coletta, SaraMembro del Collaboration Group
;Giacometti, SofiaMembro del Collaboration Group
;Pizzini, SimoneMembro del Collaboration Group
;Munari, FabioMethodology
;Gnoato, NicolòMembro del Collaboration Group
;Fassan, MatteoMembro del Collaboration Group
;Spolverato, GayaData Curation
;Calura, EnricaSupervision
;Codolo, Gaia
Conceptualization
2024
Abstract
Tumor-associated macrophages (TAMs) are the predominant immune population within the tumor microenvironment (TME), playing a key role in promoting tumor growth and establishing an immunosuppressive environment that facilitate immune evasion. Here we report that the immune receptor CD300e is highly expressed by TAM in colorectal (CRC) and drives their immunosuppressive and pro-tumorigenic, correlating with reduced expression of MHC-II molecules, essential for antigen presentation. In vitro, CD300e-deficient macrophages exhibit enhanced pro-inflammatory activity and phagocytic capacity, coupled with reduced efferocytosis, suggesting a critical role for CD300e in promoting tumor progression. The depletion of CD300e, in vivo, results in a reduced tumor burden and enhanced survival in CRC mouse models, accompanied by a more robust anti-tumor immune response characterized by increased infiltration of activated CD4+ and CD8+ T cells producing IFN-γ. Our study provides comprehensive insights into the roles of CD300e in myeloid cells in CRC, highlighting its potential as a therapeutic target for reprogramming TAMs to support anti-tumor immunity.File | Dimensione | Formato | |
---|---|---|---|
Barizza, Vassallo et al Biorxiv 01 09 2024 .pdf
accesso aperto
Tipologia:
Preprint (AM - Author's Manuscript - submitted)
Licenza:
Accesso libero
Dimensione
10.18 MB
Formato
Adobe PDF
|
10.18 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.